Literature DB >> 8177362

[Reversible hypokalemia and hypomagnesemia during alcohol withdrawal syndrome].

G Carl1, E Holzbach.   

Abstract

The alcohol-withdrawal syndrome was examined in 76 persons suffering from chronic alcohol dependency. Twenty persons showed only slight withdrawal symptoms. Thirty-two showed pronounced predelirium. Twenty-four patients developed delirium tremens. Commencing on the day on which alcohol was last consumed, potassium and magnesium levels in the blood serum were measured for 8 days until the 7th day after withdrawal from alcohol. The more pronounced the alcohol withdrawal syndrome, the sharper the decline in the level of potassium and magnesium in the blood serum. In each case, the decline in the magnesium serum level preceded that of the potassium serum level by one day. On the basis of the clinically and experimentally observed repercussions of the magnesium level (delirium symptoms, including grand mal), the magnesium blood level decline is attributed greater significance than that of the potassium blood level decline. The repercussions on magnesium and potassium blood levels resulting from the accompanying catecholamine release and of hyperventilation during delirium are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8177362

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  2 in total

Review 1.  Magnesium, Calcium, Potassium, Sodium, Phosphorus, Selenium, Zinc, and Chromium Levels in Alcohol Use Disorder: A Review.

Authors:  Jacek Baj; Wojciech Flieger; Grzegorz Teresiński; Grzegorz Buszewicz; Ryszard Sitarz; Alicja Forma; Kaja Karakuła; Ryszard Maciejewski
Journal:  J Clin Med       Date:  2020-06-18       Impact factor: 4.241

2.  Risk factors for lethal outcome in patients with delirium tremens - psychiatrist's perspective: a nested case-control study.

Authors:  Dragana Ignjatovic-Ristic; Nemanja Rancic; Slobodan Novokmet; Slobodan Jankovic; Srdjan Stefanovic
Journal:  Ann Gen Psychiatry       Date:  2013-12-02       Impact factor: 3.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.